Is Innova Captab overvalued or undervalued?

As of 17 October 2025, the valuation grade for Innova Captab has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently assessed as undervalued. Key ratios include a PE Ratio of 35.46, an EV to EBITDA of 24.85, and a PEG Ratio of 0.99, which suggests that the stock is priced favorably relative to its growth prospects.
Innova Captab's valuation stands in contrast to peers such as Sun Pharma, which is considered expensive with a PE of 35.16, and Cipla, which is also attractive but has a significantly lower PE of 23.63. This peer comparison highlights Innova Captab's relative value within the pharmaceuticals and biotechnology sector. Notably, while the stock has underperformed the Sensex year-to-date with a decline of 27.15% compared to the index's gain of 7.44%, its attractive valuation metrics suggest potential for future growth.